CCM
LRMR icon

CAAS Capital Management’s Larimar Therapeutics LRMR Stock Holding History

CAAS Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-219,147
Closed -$3.2M – 1175
2021
Q1 		$3.2M Buy
+219,147
New +$3.98M 0.03% 465

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAAS Capital Management's LRMR Position: Q2 2021 in Review

CAAS Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2021, closing a stake of 219,147 shares — an estimated $3.2M sold.

CAAS Capital Management first reported a position in LRMR in Q1 2021 and held it in 1 quarter. The position peaked at $3.2M in Q1 2021. 45 funds tracked by Wall St. Rank hold LRMR as of Q2 2021.

  • CAAS Capital Management reported no remaining Larimar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 219,147 Larimar Therapeutics shares in Q2 2021, an estimated $3.2M.
  • CAAS Capital Management first reported a position in Larimar Therapeutics in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Larimar Therapeutics position peaked at $3.2M in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.